Erythropoietin/EPO Antibody (148436) [Unconjugated]

Recombinant Mouse Erythropoietin/EPO (Catalog # 959‑ME) stimulates proliferation in the TF‑1 human erythro­leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recom­binant Mouse Erythropoietin/EPO (10 ng/mL) is neutralized (green line) by increasing concen­trations of Rat Anti-Mouse Erythropoietin/EPO Monoclonal Antibody (Catalog # MAB9591). The ND50 is typically 0.15‑0.75 µg/mL.

• Reactivity: Mu
• Applications: B/N, ELISA(Cap)
• Clone: 148436
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

Erythropoietin/EPO Antibody (148436) [Unconjugated] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant mouse Erythropoietin/EPO
  Ala27-Arg192
  Accession # P07321
• Specificity: Detects mouse Erythropoietin/EPO in direct ELISAs. In direct ELISAs, approximately 25-50% cross-reactivity with recombinant rat Erythropoietin/EPO, 5-15% cross-reactivity with recombinant human Erythropoietin/EPO, and no cross-reactivity with recombinant mouse Thrombopoietin is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: EPO
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.5-2.0 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 0.15-0.75 ug/mL
• Application Notes: ELISA Detection: Mouse Erythropoietin Biotinylated Antibody (Catalog number BAM9592)
  Standard: Recombinant Mouse Erythropoietin (Catalog number 959-ME)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Erythropoietin/EPO Antibody (148436) [Unconjugated]

• ECYT5
• EP
• EPO
• epoetin
• Erythropoietin
• MGC138142
• MVCD2

Background

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin (1). Its three N‑glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species (2, 3). Glycosylation of EPO is required for biological activities in vivo (4). Mature mouse EPO shares 95% amino acid sequence identity with rat EPO and 73%‑82% with bovine, canine, equine, feline, human, ovine, and porcine EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules (5). It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain (6‑8). EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the EPO receptor (EPO R) (8, 9). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells (7, 8, 10, 11). Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation (1, 12). Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha (1, 6). EPO additionally plays a tissue‑protective role in ischemia by blocking apoptosis and inducing angiogenesis (7, 8, 13).

1. Koury, M. J. (2005) Exp. Hematol. 33:1263.
2. Shoemaker, C.B. and L.D. Mitsock (1986) Mol. Cell. Biol 6:849.
3. Wen, D. et al. (1993) Blood 82:1507.
4. Tsuda E. et al. (1990) Eur. J. Biochem. 188:405.
5. Lacombe, C. et al. (1988) J. Clin. Invest. 81:620.
6. Eckardt, K. U. and A. Kurtz (2005) Eur. J. Clin. Invest. 35 Suppl. 3:13.
7. Sharples, E. J. et al. (2006) Curr. Opin. Pharmacol. 6:184.
8. Rossert, J. and K. Eckardt (2005) Nephrol. Dial. Transplant 20:1025.
9. Koury, M.J. and M.C. Bondurant (1990) Science 248:378.
10. Acs, G. et al. (2001) Cancer Res. 61:3561.
11. Hardee, M.E. et al. (2006) Clin. Cancer Res. 12:332.
12. Verdier, F. et al. (2000) J. Biol. Chem. 275:18375.
13. Kertesz, N. et al. (2004) Dev. Biol. 276:101.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Erythropoietin/EPO Antibody (MAB9591)(1)

Publication using MAB9591

• I Flamme, P Ellinghaus, D Urrego, T Krüger FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase PLoS ONE, 2017-10-26;12(10):e0186979. 2017-10-26 [PMID: 29073196] (Neutralization, Rat)

Bioinformatics

• Gene Symbol: EPO
• Uniprot:
  • P07321()